The FDA is currently looking into at least 22 cases of secondary malignancies in patients after receiving CAR-T therapies, according to a perspective piece from two agency officials published Wednesday in The New England Journal of Medicine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,